BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15377852)

  • 1. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
    Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
    Breast Cancer Res Treat; 2004 Sep; 87(1):65-74. PubMed ID: 15377852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
    Schindlbeck C; Kampik T; Janni W; Rack B; Jeschke U; Krajewski S; Sommer H; Friese K
    Breast Cancer Res; 2005; 7(6):R1174-85. PubMed ID: 16457698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
    Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
    Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
    Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
    J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
    Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
    Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus.
    Janni W; Hepp F; Strobl B; Rack B; Rjosk D; Kentenich C; Schindlbeck C; Hantschmann P; Pantel K; Sommer H; Braun S
    Cancer; 2003 Jan; 97(2):405-11. PubMed ID: 12518364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
    Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W
    Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
    Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.
    Saha S; Ali S; Ghanem M; Soni M; Wiese D; Arora M; Singh T; Iddings D
    Ann Surg Oncol; 2009 Feb; 16(2):276-80. PubMed ID: 19050967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
    Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
    Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
    Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer?
    Ruffato A; Mattioli S; Pileri S; Daddi N; D'Ovidio F; Pilotti V; Tazzari P
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):463-8. PubMed ID: 19150243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of the hemoglobin concentration on the hematogenous tumor cell dissemination at the time of the initial diagnosis of breast cancer].
    Janni W; Strobl B; Rack B; Rjosk D; Schindlbeck C; Hantschmann P; Kentenich C; Sigg W; Zerzer M; Sommer H
    Dtsch Med Wochenschr; 2002 Jan; 127(3):71-7. PubMed ID: 11797143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.